This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

On-Q-ity Presents Data On The Capture And HER-2 Characterization Of Circulating Tumor Cells From Metastatic Breast Cancer Patients With New Microfluidic Device

"This data is further evidence that our dual-capture chip may be a promising predictive diagnostic tool for cancer patients and their physicians, from early detection of CTCs to the prediction of the success of a specific therapy to real-time monitoring of therapy effectiveness and early detection of recurrence," said Mara G. Aspinall, President and CEO of On-Q-ity. "Our chip is highly unique in this burgeoning field as it is able to capture CTCs via size and affinity, a dual-capture screen that is more precise and effective than either method alone."

About On-Q-ity

On-Q-ity is a next-generation diagnostics company transforming cancer treatment through non-invasive diagnostic monitoring. The company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the efficacy of treatment. Headquartered in Waltham, MA, On-Q-ity is funded by Atlas Venture, Bessemer Venture Partners, MDV-Mohr Davidow Ventures, Northgate Capital and Physic Ventures. For more information: www.On-Q-ity.com

CONTACT:  Continuum Health
          Media Contact:
          Terri Clevenger
          203-227-0209
          tclevenger@continuumhealthcom.com

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,081.81 -81.18 -0.45%
S&P 500 2,115.83 -7.65 -0.36%
NASDAQ 5,091.4890 -15.1040 -0.30%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs